VRTX (STOCKS)
Vertex Pharmaceuticals Inc
$457.008000
-6.472000 (-1.40%)
Prev close: $463.480000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Reshma Kewalramani
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $117,025.35M
- Employees
- 6,100
- P/E (TTM)
- 32.67
- P/B (TTM)
- 6.80
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $11.72B |
| Benefits Costs and Expenses | $7.27B |
| Cost Of Revenue | $1.61B |
| Costs And Expenses | $7.73B |
| Gross Profit | $10.11B |
| Operating Expenses | $6.12B |
| Selling, General, and Administrative Expenses | $1.64B |
| Other Operating Expenses | $4.48B |
| Operating Income/Loss | $3.99B |
| Income/Loss From Continuing Operations After Tax | $3.68B |
| Income/Loss From Continuing Operations Before Tax | $4.45B |
| Income Tax Expense/Benefit | $773.60M |
| Net Income/Loss | $3.68B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $3.68B |
| Net Income/Loss Available To Common Stockholders, Basic | $3.68B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $14.31 |
| Diluted Earnings Per Share | $14.21 |
| Basic Average Shares | 512,200,000 |
| Diluted Average Shares | 516,600,000 |
| Assets | $24.86B |
| Current Assets | $10.57B |
| Inventory | $1.63B |
| Other Current Assets | $8.94B |
| Noncurrent Assets | $14.29B |
| Intangible Assets | $429.80M |
| Other Non-current Assets | $13.86B |
| Liabilities | $7.54B |
| Current Liabilities | $4.48B |
| Accounts Payable | $420.30M |
| Other Current Liabilities | $4.06B |
| Noncurrent Liabilities | $3.07B |
| Equity | $17.32B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $17.32B |
| Liabilities And Equity | $24.86B |
| Net Cash Flow From Operating Activities | $3.72B |
| Net Cash Flow From Operating Activities, Continuing | $3.72B |
| Net Cash Flow From Investing Activities | -$1.48B |
| Net Cash Flow From Investing Activities, Continuing | -$1.48B |
| Net Cash Flow From Financing Activities | -$2.58B |
| Net Cash Flow From Financing Activities, Continuing | -$2.58B |
| Exchange Gains/Losses | $36.30M |
| Net Cash Flow | -$300.30M |
| Net Cash Flow, Continuing | -$336.60M |
| Comprehensive Income/Loss | $3.58B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $3.58B |
| Other Comprehensive Income/Loss | $3.58B |
| Other Comprehensive Income/Loss Attributable To Parent | -$93.30M |